Market Reports Forecast Strong Growth Across Clinical Trials Segments Through 2035

New market research reports project strong growth across several clinical trials market segments, with decentralized clinical trials expected to reach USD 38.3 billion by 2035 and omics-based clinical trials forecast to reach USD 47.78 billion by 2030. The reports also cover decentralized neurology trials, women's clinical trials and CROs, and clinical trials support software.

The global decentralized clinical trials market was valued at approximately USD 9.9 billion in 2025, is expected to reach USD 11.3 billion in 2026, and is projected to grow to around USD 38.3 billion by 2035, at a CAGR of about 14.5% over 2026–2035. Digital health tools such as wearable devices, mobile health apps, electronic patient-reported outcomes (ePRO), telemedicine platforms, and electronic consent (eConsent) have been the predominant factor driving industry growth by enabling remote, real-time, patient-centered trial execution. Contract research organizations are catering to demand with end-to-end decentralized and hybrid trial services.

In the neurology-specific segment, the global decentralized clinical trials in neurology market was USD 1.48 billion in 2025 and is expected to increase from USD 1.71 billion in 2026 to approximately USD 6.38 billion by 2035, at a CAGR of 15.80%. North America led the market with a 43% share in 2025, while Asia-Pacific is expected to be the fastest-growing region at an 18.9% CAGR. By indication, Alzheimer's disease held a dominant 30% share in 2025. By trial phase, the phase III segment accounted for 42% of revenue in 2025; by trial model, hybrid decentralized trials held a 63% share; by technology, wearable devices and remote monitoring led with 32%; and by end user, pharmaceutical companies led with 58%.

The global women's clinical trials and CRO market is valued at USD 9.9 billion in 2026 and forecast to reach USD 22.3 billion by 2036, growing at a CAGR of 8.5%. The trajectory is driven by the rising prevalence of women-predominant conditions, expanding regulatory requirements for sex-specific safety evaluation, and growing adoption of precision medicine and biomarker-driven approaches. In 2025, Lindus Health launched hybrid women's health trials in oncology and reproductive medicine, leveraging more than 30 million electronic health records to double enrollment speed compared with traditional CRO approaches. The report notes that U.S.–China tariff friction is disrupting biospecimen flows and central laboratory operations, prompting some sponsors to shift recruitment and site activation toward CRO networks in India, Southeast Asia, and Europe.

The omics-based clinical trials market is expected to grow from USD 31.71 billion in 2025 to USD 34.49 billion in 2026, and to USD 47.78 billion by 2030, with CAGRs of 8.8% and 8.5%. Drivers include the adoption of precision medicine, increased investment in data-driven trials, AI-enhanced patient recruitment, regulatory acceptance of omics endpoints, and demand for efficient outcomes. The FDA approved 16 new personalized treatments in 2023, including oncology therapies. In June 2025, Bruker Corporation acquired Biocrates Life Sciences AG to enrich its multiomics solutions through metabolomics technology integration. North America leads the market, while Asia-Pacific is poised for rapid expansion. Tariffs are hiking costs for imported sequencing tools and extending study budgets.

The global clinical trials support software solutions market was valued at USD 12.99 billion in 2025, calculated at USD 14.31 billion in 2026, and is expected to reach around USD 34.15 billion by 2035, growing at a CAGR of 10.15%. North America accounted for the largest share in 2025, and Asia Pacific is expected to grow at the fastest CAGR. By product, the CTMS segment registered dominance in 2025, with the payments/investigator payment solutions segment expected to grow at the fastest CAGR; by delivery mode, cloud and web-based led the market in 2025; by phase, the phase III segment dominated; and by end-use, the CROs segment led. In May 2025, the World Health Organization launched a global action plan aimed at strengthening clinical trial ecosystems worldwide. In November 2025, SAS launched SAS Clinical Acceleration to modernize clinical trial processes, and in May 2025, PhaseV closed a USD 50 million Series A funding round co-led by Accel and Insight Partners, increasing its total funding to USD 65 million.